GeoVax Labs' (NASDAQ:GOVX) Chief Scientific Officer, Mark J. Newman, discussed the company's vaccine design strategy for developing a universal SARS-CoV-2 vaccine and presented efficacy and immunogenicity data for the Company’s lead and first-generation vaccine candidate, GEO-CM02, which encodes the Spike (S), Membrane (M) and Envelope (E) proteins at the World Vaccine & Immunotherapy Congress, being held November 30 – December 2 in San Diego, California.
Shares up 5.8% premarket at $4.37.
Dr. Newman commented, “Our studies continue to support the use of MVA as a vector for the design and production of next-generation vaccines encoding multiple coronavirus proteins. The lead candidate encodes the S protein as the antibody target and the M and E proteins as T-cell targets. The combination of S, M and E protein expression supports in vivo VLP formation and optimal immunogenicity."
"In our small animal studies, we measured functional immune responses after a single dose that mediated protection from infection and pathogenesis, including protection against the more virulent Beta variant,” he further added.